Belpointe Asset Management LLC Grows Stake in Pfizer Inc. (NYSE:PFE)

Belpointe Asset Management LLC boosted its stake in Pfizer Inc. (NYSE:PFE) by 2.4% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 231,398 shares of the biopharmaceutical company’s stock after buying an additional 5,333 shares during the quarter. Belpointe Asset Management LLC’s holdings in Pfizer were worth $6,713,000 at the end of the most recent reporting period.

Several other institutional investors also recently bought and sold shares of the company. Nordea Investment Management AB boosted its stake in shares of Pfizer by 36.1% in the fourth quarter. Nordea Investment Management AB now owns 4,071,700 shares of the biopharmaceutical company’s stock worth $108,002,000 after acquiring an additional 1,080,822 shares during the last quarter. Parsons Capital Management Inc. RI lifted its holdings in Pfizer by 118.7% in the 4th quarter. Parsons Capital Management Inc. RI now owns 294,764 shares of the biopharmaceutical company’s stock valued at $7,820,000 after purchasing an additional 159,984 shares in the last quarter. Copley Financial Group Inc. purchased a new stake in shares of Pfizer during the third quarter worth $577,000. Mcdonald Partners LLC raised its position in shares of Pfizer by 9.9% in the fourth quarter. Mcdonald Partners LLC now owns 110,296 shares of the biopharmaceutical company’s stock valued at $2,926,000 after buying an additional 9,963 shares during the last quarter. Finally, Merit Financial Group LLC lifted its stake in shares of Pfizer by 60.8% in the fourth quarter. Merit Financial Group LLC now owns 127,967 shares of the biopharmaceutical company’s stock worth $3,395,000 after buying an additional 48,397 shares in the last quarter. 68.36% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

PFE has been the subject of a number of recent research reports. The Goldman Sachs Group reiterated a “neutral” rating and issued a $25.00 price objective (down previously from $32.00) on shares of Pfizer in a report on Tuesday, April 8th. Citigroup reaffirmed a “neutral” rating on shares of Pfizer in a report on Thursday, March 27th. Hsbc Global Res raised Pfizer to a “strong-buy” rating in a research note on Monday, March 10th. UBS Group reduced their price target on Pfizer from $28.00 to $24.00 and set a “neutral” rating on the stock in a report on Tuesday, April 8th. Finally, Guggenheim reissued a “buy” rating on shares of Pfizer in a report on Tuesday, March 18th. One equities research analyst has rated the stock with a sell rating, eight have given a hold rating, six have issued a buy rating and three have given a strong buy rating to the stock. According to data from MarketBeat.com, Pfizer presently has an average rating of “Moderate Buy” and an average price target of $31.07.

Insider Buying and Selling at Pfizer

In other Pfizer news, Director Ronald E. Blaylock acquired 19,457 shares of the stock in a transaction dated Thursday, February 13th. The stock was acquired at an average price of $25.65 per share, with a total value of $499,072.05. Following the completion of the purchase, the director now owns 27,707 shares in the company, valued at $710,684.55. This trade represents a 235.84 % increase in their position. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. 0.06% of the stock is currently owned by corporate insiders.

Pfizer Stock Performance

NYSE:PFE opened at $21.89 on Monday. Pfizer Inc. has a fifty-two week low of $20.92 and a fifty-two week high of $31.54. The company has a debt-to-equity ratio of 0.63, a quick ratio of 0.73 and a current ratio of 1.00. The company has a 50 day moving average price of $25.25 and a 200 day moving average price of $26.38. The stock has a market capitalization of $124.14 billion, a P/E ratio of 15.52, a PEG ratio of 0.64 and a beta of 0.67.

Pfizer (NYSE:PFE) last released its quarterly earnings results on Tuesday, February 4th. The biopharmaceutical company reported $0.63 EPS for the quarter, topping the consensus estimate of $0.48 by $0.15. The business had revenue of $17.76 billion during the quarter, compared to analyst estimates of $17.26 billion. Pfizer had a return on equity of 19.47% and a net margin of 12.62%. The company’s quarterly revenue was up 24.7% on a year-over-year basis. During the same period last year, the business posted $0.10 earnings per share. Equities research analysts forecast that Pfizer Inc. will post 2.95 EPS for the current year.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.